These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38664918)

  • 1. Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
    Huo W; Gao L; Song K; Huang J; Wang N; Cao L; Liu Y; Wang F; Li C; Zhu X; Wu X; Cao Y; Mo X; Hu X
    Br J Haematol; 2024 Jun; 204(6):2390-2399. PubMed ID: 38664918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
    Luo L; Jiao Y; Li Y; Yang P; Gao J; Huang S; Huang W; Wang J; Dong F; Ke X; Zou D; Gao C; Jing H
    Ann Hematol; 2024 Jun; 103(6):2073-2087. PubMed ID: 38581546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
    Yasuda S; Najima Y; Konishi T; Yamada Y; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Shingai N; Yoshioka K; Inamoto K; Mukae J; Toya T; Igarashi A; Shimizu H; Kobayashi T; Kakihana K; Sakamaki H; Kawamata N; Ohashi K; Doki N
    Leuk Res; 2021 Sep; 108():106627. PubMed ID: 34062327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy.
    Cao XY; Zhang JP; Lu Y; Zhao YL; Liu DY; Xiong M; Sun RJ; Wei ZJ; Zhou JR; Zhang X; Yang JF; Li J; Lu P
    Br J Haematol; 2024 Jun; 204(6):2351-2364. PubMed ID: 38613241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation.
    Cao X; Li Z; Zhang Y; Cui Q; Dai H; Ma Y; Li M; Chen S; Yin J; Cui W; Chen J; Sun A; Qiu H; Chen S; Zhu X; Andersson BS; Wu D; Tang X
    Ann Hematol; 2024 Aug; 103(8):3083-3093. PubMed ID: 38900303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma].
    Luo L; Jiao Y; Yang P; Li Y; Huang WY; Ke XY; Zou DH; Jing HM
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):388-394. PubMed ID: 37550188
    [No Abstract]   [Full Text] [Related]  

  • 8. Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study.
    Gu Z; Li F; Li M; Wang L; Lu N; Jin X; Wang L; Gao C; Dou L; Liu D
    Ann Hematol; 2024 Jul; 103(7):2445-2454. PubMed ID: 38605231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TBI/Cy followed by auto-HSCT is a good choice next to allo-HSCT for patients with T-LBL/ALL.
    Mao J; Ge J; Ding S; Sun Z; Nan F; Yu H; Ding J; Wang X; Liu Z; Zhang M; Fu X
    Sci Rep; 2024 Sep; 14(1):22356. PubMed ID: 39333693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China.
    Gu ZY; Dong YJ; Fu XR; Li NN; Liu Y; Wu XX; Wang YN; Li YH; Ren HY; Zhang MZ; Li XF; Wang MH; Wu YM; Liu DH; Wang Z; Hu LD; Huang WR
    Chin Med J (Engl); 2021 Jun; 134(13):1584-1592. PubMed ID: 34133361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party.
    El Cheikh J; Ngoya M; Galimard JE; Reményi P; Kulagin A; Aljurf M; Mousavi A; Wu D; Ozcelik T; Salmenniemi U; Castilla-Llorente C; Socie G; Helbig G; Schroeder T; Sakellari I; Rambaldi A; Burt R; Busca A; Balsat M; Stelljes M; Brissot E; Giebel S; Peric Z; Nagler A; Bazarbachi A; Ciceri F; Mohty M
    Bone Marrow Transplant; 2024 Sep; 59(9):1239-1246. PubMed ID: 38834689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma.
    Li Z; Zhang B; Fan X; Gui R; Yu F; Wang J; Zhang Y; Zhou K; Liu Y; Li Y; Ding J; Song Y; Zhou J
    Front Oncol; 2023; 13():1193237. PubMed ID: 37546390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
    Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
    Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.
    Yu J; Luo Y; Wang L; Wang T; Ye M; Chen J; Ni X; Chen L; Gao L; Yang J
    Cancer Med; 2024 May; 13(10):e7310. PubMed ID: 38785213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
    Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
    [No Abstract]   [Full Text] [Related]  

  • 18. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
    Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.